PECULIARITIES OF GLUCOSE METABOLISM IN LEWIS LUNG CARCINOMA CELLS WITH DIFFERENT METASTATIC POTENTIAL
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-4-2019-g.8326Keywords:
glucose, lactate, Lewis lung carcinoma, metabolismAbstract
Aim: to study the peculiarities of glucose metabolism in tumor cells of two variants of Lewis lung carcinoma with different metastatic and angiogenic potentials. Object and methods: in vitro study was carried out using cultured LLC and LLC/R9 cell lines, and in vivo on С57/BL6 female mice. There were a total of 40 animals used. It is known that two variants of Lewis lung carcinoma, LLC and LLC/R9, are tumors of the same genesis, but have different biological properties: LLC/R9 in comparison with LLC is characterized by higher proliferative, angiogenic and lower metastatic (according to the volume and number of pulmonary metastases) potentials. Methods of experimental oncology, cell culture, biochemical and statistical methods have been used. Results: it was revealed that LLC/R9 cells characterized by 37.3% (p < 0.05) higher rate of glucose consumption and in 50.6% (p < 0.05) higher lactate production rate in comparison with corresponding high-metastatic variant of Lewis lung carcinoma cells. The lactate and pyruvate levels in the tumor tissue of high-angiogenic variant of Lewis lung carcinoma were found to be significantly lower than the respective rates for the high-metastatic variant by 24.0% (p < 0.05) and 56.0% (p < 0.05). It was shown that blood glucose level in LLC-bearing animals exceeded intact and LLC/R9 index by 30.0% (p < 0.05) and 33.5% (p < 0.05), respectively, and the rate of lactate tended to decrease. Conclusions: it was found that glucose metabolism of LLC cells considerably differ from that of LLC/R9 cells. As compared to LLC, LLC/R9 cells are characterized by high levels of glucose consumption, which results in their rapid in vivo growth and low blood glucose level in LLC/R9-bearing mice.
References
Liberti MV, Locasale JW. The warburg effect: how does it benefit cancer cells? Trends Biochem Sci 2016; 41 (3): 211–18.
Gouirand V, Guillaumond F, Vasseur S. Influence of the tumor microenvironment on cancer cells metabolic reprogramming. Front Oncol 2018; 8: doi: 10.3389/fonc.2018.00117.
Solyanik GI, Pyaskovskaya ON, Garmanchuk LV. Cisplatin-resistant Lewis lung carcinoma cells possess increased level of VEGF secretion. Exp Oncol 2003; 4; 260–5.
Pyaskovskaya ON, Dasyukevich OI, Kolesnik DL, et al. Changes in VEGF level and tumor growth characteristics during Lewis lung carcinoma progression towards cis-DDP resistance. Exp Oncol 2007; 29 (3); 197–202.
Sorokina LV, Boichuk IV, Melnikov OR, et al. Peculiarities of the antioxidant system of blood plasma in mice with highly angiogenic Lewis lung carcinoma. Rep NASU 2012; 1; 174–9 (in Ukrainian).
Pyaskovskaya ON, Sorokina LV, Kolesnik DL, et al. Dynamics of changes of antioxidant system indexes during the growth of two Lewis lung carcinoma variants. Ехp Oncol 2012; 36 (1); 29–33.
Kumari S, Badana AK, G MM, et al. Reactive oxygen species: a key constituent in cancer survival. Biomark Insights 2018; 13: 1177271918755391.
Rezyapkin VI, Slyshenkov VS, Breeder IB, et al. Laboratory practice in biochemistry and biophysics. Grodno: GrSU, 2009. 175 p (in Russian).
Stokkel MP, Broek FW, van Rijk PP. The role of FDG PET in the clinical management of head and neck cancer. Oral Oncol 1998, 34: 466–71.
Visser FC. Imaging of cardiac metabolism using radiolabelled glucose, fatty acids and acetate. Coron Artery Dis 2001; 12 (1): 12–8.
Kolesnik DL, Pyaskovskaya ON, Dasyukevich OI, et al. Significant antimetastatic efficacy of metronomic low-dose oral cyclophosphamide against highly angiogenic variant of Lewis lung carcinoma/International conference «Tumor and host: Novel aspects of old problem», Kiev, 21–24 September, 2010. Exp Oncol 2011; 33 (1): 94.
Wegiel B, Vuerich M, Daneshmandi S, et al. Metabolic switch in the tumor microenvironment determines immune responses to anti-cancer therapy. Front Oncol 2018; 8: 284.
Muir A, Danai LV, G M. et al. Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies. Dis Model Mech 2018; 11 (8): dmm035758.
Rimachi R, Bruzzi de Carvahlo F, Orellano-Jimenez C, et al. Lactate/pyruvate ratio as a marker of tissue hypoxia in circulatory and septic shock. Anaesth Intensive Care 2012; 40 (3): 427–32.
Rajendran JG, Mankoff DA, O’Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18f]fluoromisonidazole and [18f]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10: 2245–52.
San-Millán I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis 2017; 38 (2): 119–33.
Wu Yo, Dong Yu, Atefi M, et al. Lactate, a neglected factor for diabetes and cancer interaction. Mediators Inflamm 2016: 6456018.
